ClinicalTrials.gg
TerminatedNCT01964378CORALUpdated Jul 15, 2021Results posted

CORAL - Cebranopadol Versus Morphine Prolonged-release in Patients With Chronic Moderate to Severe Pain Related to Cancer

A Phase 3 interventional study of Cebranopadol and Morphine Prolonged Release in Pain, Neoplasms and Chronic Pain, sponsored by Tris Pharma, Inc.. Terminated at 42 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-07-15.

Primary conditionChronic PainRegistry: PainReclassifiedWhy we changed it
Registry
Pain — the first condition term the registry derived for this study.
ClinicalTrials.gg
Chronic Pain
Why
  1. The study's listed conditions name Chronic Pain, a narrower term within Pain.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Tris Pharma, Inc. · Phase 3, Interventional, and Treatment

Why this study was terminated
low accrual made the study no longer feasible/decision not related to safety and efficacy

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 21 studies in Chronic Pain with a site in Poland — 5 open to participants now, 5 under way, none of them phase 3. Chronic Pain · Poland.

Enrollment
5th of 16
200 · median 79
Started
2013
with 1 other
Phase 3
8 of 21
none open now
Registered
9th of 21
by date
Lead sponsor
2 of 21
Tris Pharma, Inc.

Among the 21 studies in Chronic Pain with a site in Poland, this one is the 5th largest by enrollment of the 16 interventional ones that give a count, is one of 2 that started in 2013, is one of 8 in phase 3, and was the 9th registered.

Chronic Pain

3,228 studies on the registry are indexed under Chronic Pain; 728 are open to participants now.

Browse Chronic Pain studies →

Open to participants now

5 of the 21 studies in Chronic Pain with a site in Poland are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →

Who these studies take

Of the 486 Chronic Pain studies recruiting now, 239 (49%) set no upper age limit and 173 (36%) stop at 75 or younger; 43 take children under 18; 64 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Chronic Pain with a site in Poland, or all of them as a file.
02

Study summary

Pain is one of the most common symptoms associated with malignant tumor. The purpose of this trial is to determine whether cebranopadol is as effective in patients with cancer related pain as morphine sulfate prolonged release (PR).

Read the detailed description

The trial comprises an enrollment period, a treatment period (titration and maintenance), and a follow-up period. Participants will receive either cebranopadol or morphine PR for 44 days. Initially participants will be titrated after 2 and then every 4 days to a morphine PR or cebranopadol dose that provides adequate analgesia and is tolerated. The titration period is planned to last 16 days. Thereafter the dose of morphine PR or cebranopadol is to be kept stable for a further 28 days, i.e. no dose adjustments will be allowed during the maintenance period. This 28 day period is the maintenance period. The follow-up period is planned for up to 18 days after the end of last pain medication treatment intake.

03

Conditions studied

  • Pain
  • Neoplasms
  • Chronic Pain

Browse trials for

Keywords

  • cancer pain
  • neuropathic related cancer pain
  • morphine
  • cebranopadol (GRT6005)
  • Numerical Rating Scale
04

In context

Chronic Pain Reclassified

3,228 studies on the registry are indexed under Chronic Pain; 728 are open to participants now.

This study's enrollment of 200 is above the median of 60 across 2,387 interventional studies indexed under Chronic Pain.

Browse Chronic Pain studies →

Lead sponsor

Tris Pharma, Inc. is the lead sponsor of 22 studies on the registry; none are open to participants now.

Of its 13 completed or terminated interventional studies of FDA-regulated products, 4 (31%) have results posted.

Compared within Chronic Pain, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Pain. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed .
  2. Negative pregnancy test before first dose.
  3. Female and male participants willing to use acceptable and highly effective methods of .
  4. The following criteria must be fulfilled by participants:

    1. Require daily analgesia for their pain,
    2. Diagnosed with active cancer,
    3. Receiving daily opioid treatment at doses not higher than 90 mg oral morphine or its equivalent (World Health Organization Step II and Step III analgesics) for an appropriate length of time,
    4. Participants must be dissatisfied with their current pain treatment,
    5. Participants must be suffering from cancer-related but not cancer therapy-related chronic pain for a period of 4 weeks or more prior to enrollment.
  5. Eastern Cooperation Oncology Group () score 2 or below.
  6. Average pain intensity over the last 24 hours of 5 or more calculated from the pain assessments recorded during the last 3 days prior to randomization.
  7. Compliance with the use of the electronic diary defined as at least 3 out of 4 of the 24 hour Numerical Rating Scale entries available during the last 4 days prior to and including the day of allocation to treatment.

Exclusion criteria

Exclusion Criteria:

  1. Evidence of ongoing alcohol and or drug abuse and/or a history of alcohol and/or drug abuse within the last 2 years.
  2. A disease other than cancer which in the investigator's opinion may affect efficacy or safety assessments e.g., significant unstable cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurological, infectious disease, psychiatric (resulting in disorientation, memory impairment or inability to report accurately) or metabolic disorders.
  3. Any gastrointestinal disorder that could affect the absorption and/or elimination of Medicinal Product.
  4. Any planned major surgery during the trial.
  5. Known to or suspected of not being able to comply with the trial protocol and the use of Investigational Medicinal Product.
  6. History of seizure disorder and/or epilepsy or any condition associated with a significant risk of seizure or epilepsy.
  7. Known history and/or presence of cerebral tumor or cerebral .
  8. Moderate to severe hepatic impairment corresponding to classification B and C. Impaired hepatic cellular integrity indicated by or alanine transaminase greater than 3 times the at the Enrollment Visit.
  9. Inadequate baseline bone marrow reserve with a white blood cell count below 2000/µL, a count 100 000/µL or less, and a level below 8 g/dL at the Enrollment Visit.
  10. Impaired renal function. less than 60 mL per minute(as per amendment 45 mL per minute) at the Enrollment Visit (calculated from the Cockcroft-Gault formula).
  11. Forbidden concomitant medications
  12. Uncontrolled hypertension
  13. Clinically relevant history of , allergy or to opioid medication or any of the of morphine sulfate (Prolonged Released or Immediate Release), or cebranopadol film-coated tablets.
  14. Chronic or C, or (HIV) known by history, or presence of active hepatitis B or C within the 3 months before the Enrollment Visit.
  15. History of torsade de pointes and/or presence of risk factors for torsade de pointes (e.g., heart failure, hypokalemia, or bradycardia).
  16. Marked prolongation of interval (Fridericia) (greater than 450 milliseconds) at the Enrollment Visit.
  17. Employees of the sponsor, investigator, or trial site or family members of the employees, sponsor, or investigator.
  18. Concurrent participation in another trial or planning to be enrolled in another clinical trial (i.e., administration of experimental treatment in another clinical trial) during the course of this trial.
  19. Previous participation in this or other trials with cebranopadol with the following exceptions:

    • Participants who failed enrollment in this trial only because of exclusion criterion 10, and who may now be eligible can be re-enrolled.
    • Participants who failed enrollment due to technical failure of equipment (e.g., machine and e-diary device).
  20. Participant has received an experimental drug or used an experimental medical device within 30 days before the planned start of treatment.
  21. Currently not receiving opioid treatment for cancer-related pain at the enrollment visit (i.e., opioid naïve).
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
200 participants (actual)

Study arms

  • Experimental
    Cebranopadol

    Once daily oral administration. 200, 400 or 600 µg film coated tablets. Dosage 200 µg to 1000 µg per day.

    Drug: Cebranopadol

  • Active comparator
    Morphine Prolonged Release

    Twice daily oral administration. 15, 30 or 45 mg morphine sulfate capsules. Dosage 30 to 150 mg per day.

    Drug: Morphine Prolonged Release

Interventions

  • Participant will take one or two tablet(s) of cebranopadol in the morning and one or two placebo double-dummy morphine-like capsule(s) in the morning and the evening.

    Also known as: GRT6005

  • DrugMorphine Prolonged Release

    Participant will take one or two morphine capsule(s) in the morning and in the evening and one or two placebo double-dummy cebranopadol-like tablet(s) in the morning.

07

What researchers measure

Primary outcomes

  1. Average Amount of Daily Rescue Medication at the End of the Maintenance Period (Per Protocol Set)

    Morphine sulfate immediate release (IR) 10 mg tablets were supplied as rescue medication to trial participants. No dose adjustments of the morphine prolonged release or cebranopadol were allowed during the maintenance period. The daily use of morphine sulfate 10 mg IR tablets was documented by each participant in the trial. The total daily amount of morphine IR was subject to an upper limit recommendation. The primary endpoint is the average amount of daily rescue medication intake over the last 2 weeks of the maintenance period.

    Time frame: The last 2 weeks of the expected 6-week treatment period.

  2. Average Amount of Daily Rescue Medication at the End of the Maintenance Period (Full Analysis Set)

    Morphine sulfate IR 10 mg tablets were supplied as rescue medication to trial participants. No dose adjustments of the morphine prolonged release or cebranopadol were allowed during the maintenance period. The daily use of morphine sulfate 10 mg IR tablets was documented by each participant in the trial. The total daily amount of morphine IR was subject to an upper limit recommendation. The primary endpoint is the average amount of daily rescue medication intake over the last 2 weeks of the maintenance period.

    Time frame: The last 2 weeks of the expected 6-week treatment period.

Secondary outcomes

  1. Proportion of Participants With Clinically Relevant Pain Reduction at the End of the Maintenance Period

    Each participant indicated the level of pain on an 11-point numerical rating scale (NRS), where a score of 0 indicated "no pain" and a score of 10 indicated "pain as bad as you can imagine". The participants entered their pain intensity in their diary on a daily basis. The pain intensity score in the 2 weeks prior to the final evaluation in the maintenance period was compared with the baseline, the baseline pain intensity was calculated based on the 3 days prior to treatment allocation. The definition of a clinically relevant pain reduction (yes/no) was the presence of at least 1 of the 3 following conditions: * Average pain intensity (i.e., average of the 24-hour pain intensities over the last 2 weeks of the Maintenance Phase) of less than 4 points on the 11-point NRS, or * Reduction in average pain intensity by at least 30% (compared to the baseline assessment), or * Reduction in average pain intensity by at least 2 points (compared to the baseline assessment).

    Time frame: The last 2 weeks of the expected 6-week treatment period.

Other outcomes

  1. Change in Weekly Mean of the Daily Average Pain Intensity Score From Baseline

    Participants will be asked: "Please rate your pain by selecting the one number that best describes your pain on average during the last 24 hours." every day in the morning. They will score their pain intensity on an 11-point Numerical Rating Scale (NRS) where a score of 0 indicated "no pain" and a score of 10 indicated "pain as bad as you can imagine". The weekly mean value of the 24-h average pain intensity will be calculated as a mean score of these daily entries of average pain intensity for each trial week.

    Time frame: Baseline; last 2 weeks of the expected 6-week treatment period

  2. Response Rate to Treatment

    Pain intensity will be recorded daily by each participant in the morning on an 11-point Numerical Rating Scale, ranging from 0 (no pain) to 10 (worst imaginable pain). From this, the weekly average 24-hour pain intensity will be calculated. The number of participants with a 0, 10, 20, 30, up to a 100% reduction in weekly mean pain intensity will be reported over each week and over the last 2 weeks of the maintenance period.

    Time frame: Baseline; last 2 weeks of the expected 6-week treatment period

  3. Overall Score of the Neuropathic Pain Symptom Inventory (NPSI)

    Participants with neuropathic pain (determined by the completion of the Douleur Neuropathique En 4 Questions \[DN4\] questionnaire at allocation) rated their symptoms of neuropathic pain on the Neuropathic Pain Symptom Inventory (NPSI). Ten out of 12 questions were answered on an 11-point scale 0 (no symptom present) to 10 (worst imaginable); 2 out of 12 questions assessed the duration of spontaneous pain and the number of pain attacks and were answered by selecting 1 of 5 possible responses. Mean scores of NPSI were calculated. The overall NPSI score was calculated by the summation of all responses in the ranges between 0 (all symptoms absent) and 1 (all symptoms present and at the worst intensity). A negative change indicates that the intensity of all the neuropathic symptom components have decreased since the start of treatment.

    Time frame: Baseline; End-of-Treatment Visit (Week 6)

  4. EuroQol-5 Dimension (EQ-5D) Health Questionnaire: Weighted EQ-5D Health Status Index

    The EuroQol-5 Dimension Health Questionnaire is a generic health related quality of life instrument. The participants will answer 5 questions on 5 dimensions of their health related quality of life: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each question has 3 possible answers reflecting 3 levels of impact on the quality of life. The weighted EQ-5D health status index values are derived and reported as change from baseline. The responses to the 5 EQ-5D dimensions were scored using a utility-weighted algorithm to derive an EQ-5D health status index score (with 1 indicating "full health" and 0 representing "dead"). The higher the values (the closer the value is to 1) the better the health status in a treatment group. A positive change indicates an improvement.

    Time frame: Baseline; End-of-Treatment Visit (6 weeks)

  5. EuroQol-5 Dimension (EQ-5D) Health Questionnaire: Visual Analog Scale (VAS) Score

    The EuroQol-5 Dimension Health Questionnaire is a generic health related quality of life instrument. EuroQoL-5D Health State Visual Analog Scale (VAS) is a participant rated questionnaire to assess health-related quality of life in terms of a single index value. The VAS component rates current health state on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state); higher scores indicate a better health state. The values indicated represent the change from the baseline, a positive value indicates an improvement.

    Time frame: Baseline; End-of-Treatment Visit (6 weeks)

  6. Change in the Physical and Mental Component Scores From the Short Form 12® Health Survey (SF-12)

    The Physical and Mental Component Scores are calculated from the responses by participants to 12 questions. These 12 questions cover 8 domains, (physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role participation with emotional health problems, and mental health) that a participant was asked to rate over the last week. Questions are scored on a Likert-scale. The Physical and Mental Component Scores were not derived as the trial was terminated. Changes in the individual item scores are therefore reported. A higher score indicates a better participant perceived state of health. All domains were scored on a scale from 0 (lowest level of health) to 100 (highest level of health), with 100 representing the best possible health state. If the values are positive there was an improvement. The higher the value the greater the improvement.

    Time frame: Baseline; End-of-Treatment Visit (6 weeks)

  7. Patient Global Impression of Change (PGIC)

    In the Patient Global Impression of Change (PGIC) the participant indicates the perceived change over the treatment period compared to his condition prior to the start of treatment. The participant is requested to choose one of seven categories. Scores range from very much improved to very much worse.

    Time frame: Baseline; End-of-Treatment Visit (6 weeks)

  8. Clinical Global Impression of Change (CGIC)

    In the Clinical Global Impression of Change (CGIC) the clinician indicates the perceived change in patient's condition over the treatment period as compared to patient's condition prior to the start of treatment. The clinician is requested to choose one of seven categories. Scores range from very much improved to very much worse.

    Time frame: Baseline; End-of-Treatment Visit (6 weeks)

  9. Overall Score of the Patient Assessment of Constipation Symptoms (PAC-SYM)

    The PAC-SYM is a 12-item self-administered questionnaire that assesses the severity of constipation-related symptoms during past 2 weeks. Items are rated on a 5-point Likert scale, where 0 = absent, 1 = mild, 2 = moderate, 3 = severe, 4 = very severe.The PAC-SYM contains 3 subscales: stool symptoms (5 items), abdominal symptoms (4 items), rectal symptoms (3 items). If at least 6 items are assessed, the PAC-SYM overall score is calculated as the sum of the scores of all non-missing items divided by number of non-missing items. The minimum overall score is 0, the maximum overall score is 4. If more than 6 items are missing, no overall score is calculated. Changes from baseline for the overall score are presented. If the changes in the overall (or subscale) scores are positive then there is a worsening in symptoms associated with constipation.

    Time frame: Baseline; End-of-Treatment Visit (6 weeks)

  10. Change in Weekly Mean of the Daily Worst Pain Intensity Score From Baseline

    Participants will be asked: "Please rate your pain by selecting the one number that best describes your pain at its worst during the last 24 hours." every day in the morning. They will score their pain intensity on an 11-point Numerical Rating Scale (NRS) where a score of 0 indicated "no pain" and a score of 10 indicated "pain as bad as you can imagine". The weekly mean value of the 24 h worst pain intensity will be calculated as a mean score of these daily entries of worst pain intensity for each trial week. A positive change from baseline will indicate a worsening, whilst a negative change will indicate an improvement of pain.

    Time frame: Baseline; End-of-Treatment Visit (6 weeks)

  11. Change From Baseline to End-of-Treatment Visit in Chronic Pain Sleep Inventory (CPSI) Scores

    The CPSI measures 5 items on 100-mm visual analog scales: trouble falling asleep (CPSI1), needing sleep medication (CPSI2), awakened by pain during the night (CPSI3) and in the morning (CPSI4) \[all with anchors for 0 = never and 100 = always\], and overall quality of sleep (CPSI5) \[with anchors of 0 = very poor and 100 = excellent\]. The sleep problem index is the sum of items CPSI1, CPSI3 and CPSI4. The minimum sleep problem index is 0 mm, the maximum 300 mm, the higher the worse. For the overall quality of sleep, minimum and maximum are 0 and 100 mm, the higher the better. A decrease in the sleep problem index indicates an improvement as does an increase in the overall quality of sleep. Changes from baseline to the End-of-Treatment Visit of the Maintenance Phase (scheduled for Week 6) were calculated.

    Time frame: Baseline; End-of-Treatment Visit (6 weeks)

08

Results

Posted Dec 30, 2019
Limitations and caveats
As the enrollment was stopped for business reasons, only a fraction of the planned number of participants was enrolled; however, the trial still has a larger participant number per treatment than a majority of trials in cancer pain so far.

Participant flow

The trial started on 29 Oct 2013 with the enrollment of the first subject and was completed on 16 Oct 2015 when the last subject completed the last follow-up examination.

Participant flow — Overall Study
MilestoneCebranopadolMorphine Prolonged Release
Started6666
Participants treated (safety set)6561
Completed4145
Not completed2521
Withdrew: Disc. due to death before first dosing01
Withdrew: Disc. due to ae before first dosing10
Withdrew: Death32
Withdrew: Adverse event125
Withdrew: Lack of efficacy01
Withdrew: Protocol violation01
Withdrew: Lost to follow-up01
Withdrew: Withdrawal by subject75
Withdrew: Inclusion/exclusion criteria not met13
Withdrew: Other12

Outcome measures

PrimaryAverage Amount of Daily Rescue Medication at the End of the Maintenance Period (Per Protocol Set)

Morphine sulfate immediate release (IR) 10 mg tablets were supplied as rescue medication to trial participants. No dose adjustments of the morphine prolonged release or cebranopadol were allowed during the maintenance period. The daily use of morphine sulfate 10 mg IR tablets was documented by each participant in the trial. The total daily amount of morphine IR was subject to an upper limit recommendation. The primary endpoint is the average amount of daily rescue medication intake over the last 2 weeks of the maintenance period.

Time frame:
The last 2 weeks of the expected 6-week treatment period.
Reported as:
Least squares mean · milligram(s)/24 hours
Average Amount of Daily Rescue Medication at the End of the Maintenance Period (Per Protocol Set)
milligram(s)/24 hoursCebranopadolMorphine Prolonged Release
Average Amount of Daily Rescue Medication at the End of the Maintenance Period (Per Protocol Set)4.25 ± 1.78.92 ± 1.72
Statistical analysis
  • Cebranopadol vs Morphine Prolonged Release · MMRM · p = < 0.0001 · Point-estimate: -7.48 · 95% CI -12.05 to -2.918
PrimaryAverage Amount of Daily Rescue Medication at the End of the Maintenance Period (Full Analysis Set)

Morphine sulfate IR 10 mg tablets were supplied as rescue medication to trial participants. No dose adjustments of the morphine prolonged release or cebranopadol were allowed during the maintenance period. The daily use of morphine sulfate 10 mg IR tablets was documented by each participant in the trial. The total daily amount of morphine IR was subject to an upper limit recommendation. The primary endpoint is the average amount of daily rescue medication intake over the last 2 weeks of the maintenance period.

Time frame:
The last 2 weeks of the expected 6-week treatment period.
Reported as:
Least squares mean · milligram(s)/24 hours
Average Amount of Daily Rescue Medication at the End of the Maintenance Period (Full Analysis Set)
milligram(s)/24 hoursCebranopadolMorphine Prolonged Release
Average Amount of Daily Rescue Medication at the End of the Maintenance Period (Full Analysis Set)3.46 ± 1.7110.94 ± 1.75
Statistical analysis
  • Cebranopadol vs Morphine Prolonged Release · MMRM (mixed model repeated measurement) · p = < 0.0001 (MMRM model: fixed effects of pooled country, treatment, week, treatment-by-week interaction, opioid intake history, baseline pain intensity as covariate \& subject-specific random effects. Dependent variable: weekly average rescue medication intake.) · Point-estimate: -4.67 · 95% CI -9.245 to -0.099Non-inferiority of cebranopadol compared with morphine will be established if the upper bound of the resulting 95% confidence interval for the average treatment difference is below the non-inferiority margin of 8mg.
SecondaryProportion of Participants With Clinically Relevant Pain Reduction at the End of the Maintenance Period

Each participant indicated the level of pain on an 11-point numerical rating scale (NRS), where a score of 0 indicated "no pain" and a score of 10 indicated "pain as bad as you can imagine". The participants entered their pain intensity in their diary on a daily basis. The pain intensity score in the 2 weeks prior to the final evaluation in the maintenance period was compared with the baseline, the baseline pain intensity was calculated based on the 3 days prior to treatment allocation. The definition of a clinically relevant pain reduction (yes/no) was the presence of at least 1 of the 3 following conditions: * Average pain intensity (i.e., average of the 24-hour pain intensities over the last 2 weeks of the Maintenance Phase) of less than 4 points on the 11-point NRS, or * Reduction in average pain intensity by at least 30% (compared to the baseline assessment), or * Reduction in average pain intensity by at least 2 points (compared to the baseline assessment).

Time frame:
The last 2 weeks of the expected 6-week treatment period.
Reported as:
Count of participants · Participants
Proportion of Participants With Clinically Relevant Pain Reduction at the End of the Maintenance Period
ParticipantsCebranopadolMorphine Prolonged Release
Clinically relevant pain reduction (Yes)4851
Clinically relevant pain reduction (No)1610
Other pre-specifiedChange in Weekly Mean of the Daily Average Pain Intensity Score From Baseline

Participants will be asked: "Please rate your pain by selecting the one number that best describes your pain on average during the last 24 hours." every day in the morning. They will score their pain intensity on an 11-point Numerical Rating Scale (NRS) where a score of 0 indicated "no pain" and a score of 10 indicated "pain as bad as you can imagine". The weekly mean value of the 24-h average pain intensity will be calculated as a mean score of these daily entries of average pain intensity for each trial week.

Time frame:
Baseline; last 2 weeks of the expected 6-week treatment period
Reported as:
Mean · units on a scale
Change in Weekly Mean of the Daily Average Pain Intensity Score From Baseline
units on a scaleCebranopadolMorphine Prolonged Release
Change in Weekly Mean of the Daily Average Pain Intensity Score From Baseline-3.4 ± 2.11-3.2 ± 1.60
Other pre-specifiedResponse Rate to Treatment

Pain intensity will be recorded daily by each participant in the morning on an 11-point Numerical Rating Scale, ranging from 0 (no pain) to 10 (worst imaginable pain). From this, the weekly average 24-hour pain intensity will be calculated. The number of participants with a 0, 10, 20, 30, up to a 100% reduction in weekly mean pain intensity will be reported over each week and over the last 2 weeks of the maintenance period.

Time frame:
Baseline; last 2 weeks of the expected 6-week treatment period
Reported as:
Count of participants · Participants
Response Rate to Treatment
ParticipantsCebranopadolMorphine Prolonged Release
Non-responder139
>= 0% pain reduction5152
>= 10% pain reduction5052
>= 20% pain reduction4450
>= 30% pain reduction3942
>= 40% pain reduction3137
>= 50% pain reduction2627
>= 60% pain reduction1918
>= 70% pain reduction1311
>= 80% pain reduction108
>= 90% pain reduction52
100% pain reduction32
Other pre-specifiedOverall Score of the Neuropathic Pain Symptom Inventory (NPSI)

Participants with neuropathic pain (determined by the completion of the Douleur Neuropathique En 4 Questions \[DN4\] questionnaire at allocation) rated their symptoms of neuropathic pain on the Neuropathic Pain Symptom Inventory (NPSI). Ten out of 12 questions were answered on an 11-point scale 0 (no symptom present) to 10 (worst imaginable); 2 out of 12 questions assessed the duration of spontaneous pain and the number of pain attacks and were answered by selecting 1 of 5 possible responses. Mean scores of NPSI were calculated. The overall NPSI score was calculated by the summation of all responses in the ranges between 0 (all symptoms absent) and 1 (all symptoms present and at the worst intensity). A negative change indicates that the intensity of all the neuropathic symptom components have decreased since the start of treatment.

Time frame:
Baseline; End-of-Treatment Visit (Week 6)
Reported as:
Mean · units on a scale
Overall Score of the Neuropathic Pain Symptom Inventory (NPSI)
units on a scaleCebranopadolMorphine Prolonged Release
Overall Score of the Neuropathic Pain Symptom Inventory (NPSI)-0.15 ± 0.126-0.10 ± 0.129
Other pre-specifiedEuroQol-5 Dimension (EQ-5D) Health Questionnaire: Weighted EQ-5D Health Status Index

The EuroQol-5 Dimension Health Questionnaire is a generic health related quality of life instrument. The participants will answer 5 questions on 5 dimensions of their health related quality of life: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each question has 3 possible answers reflecting 3 levels of impact on the quality of life. The weighted EQ-5D health status index values are derived and reported as change from baseline. The responses to the 5 EQ-5D dimensions were scored using a utility-weighted algorithm to derive an EQ-5D health status index score (with 1 indicating "full health" and 0 representing "dead"). The higher the values (the closer the value is to 1) the better the health status in a treatment group. A positive change indicates an improvement.

Time frame:
Baseline; End-of-Treatment Visit (6 weeks)
Reported as:
Mean · units on a scale
EuroQol-5 Dimension (EQ-5D) Health Questionnaire: Weighted EQ-5D Health Status Index
units on a scaleCebranopadolMorphine Prolonged Release
EuroQol-5 Dimension (EQ-5D) Health Questionnaire: Weighted EQ-5D Health Status Index0.1 ± 0.3310.2 ± 0.287
Other pre-specifiedEuroQol-5 Dimension (EQ-5D) Health Questionnaire: Visual Analog Scale (VAS) Score

The EuroQol-5 Dimension Health Questionnaire is a generic health related quality of life instrument. EuroQoL-5D Health State Visual Analog Scale (VAS) is a participant rated questionnaire to assess health-related quality of life in terms of a single index value. The VAS component rates current health state on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state); higher scores indicate a better health state. The values indicated represent the change from the baseline, a positive value indicates an improvement.

Time frame:
Baseline; End-of-Treatment Visit (6 weeks)
Reported as:
Mean · units on a scale
EuroQol-5 Dimension (EQ-5D) Health Questionnaire: Visual Analog Scale (VAS) Score
units on a scaleCebranopadolMorphine Prolonged Release
EuroQol-5 Dimension (EQ-5D) Health Questionnaire: Visual Analog Scale (VAS) Score-0.1 ± 22.98315.1 ± 24.305
Other pre-specifiedChange in the Physical and Mental Component Scores From the Short Form 12® Health Survey (SF-12)

The Physical and Mental Component Scores are calculated from the responses by participants to 12 questions. These 12 questions cover 8 domains, (physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role participation with emotional health problems, and mental health) that a participant was asked to rate over the last week. Questions are scored on a Likert-scale. The Physical and Mental Component Scores were not derived as the trial was terminated. Changes in the individual item scores are therefore reported. A higher score indicates a better participant perceived state of health. All domains were scored on a scale from 0 (lowest level of health) to 100 (highest level of health), with 100 representing the best possible health state. If the values are positive there was an improvement. The higher the value the greater the improvement.

Time frame:
Baseline; End-of-Treatment Visit (6 weeks)
Reported as:
Mean · units on a scale
Change in the Physical and Mental Component Scores From the Short Form 12® Health Survey (SF-12)
units on a scaleCebranopadolMorphine Prolonged Release
Physical function7.1 ± 31.049.9 ± 24.68
Role physical5.1 ± 27.236.4 ± 24.10
Bodily pain10.2 ± 29.289.0 ± 31.43
General health5.4 ± 20.139.2 ± 27.38
Vitality0.0 ± 25.0010.4 ± 28.77
Social function7.1 ± 28.875.2 ± 33.38
Role emotional3.3 ± 28.390.2 ± 27.57
Mental health3.1 ± 20.186.1 ± 21.32
Other pre-specifiedPatient Global Impression of Change (PGIC)

In the Patient Global Impression of Change (PGIC) the participant indicates the perceived change over the treatment period compared to his condition prior to the start of treatment. The participant is requested to choose one of seven categories. Scores range from very much improved to very much worse.

Time frame:
Baseline; End-of-Treatment Visit (6 weeks)
Reported as:
Count of participants · Participants
Patient Global Impression of Change (PGIC)
ParticipantsCebranopadolMorphine Prolonged Release
Very much improved53
Much improved1817
Minimally improved1717
No change410
Minimally worse44
Much worse22
Very much worse00
Missing63
Other pre-specifiedClinical Global Impression of Change (CGIC)

In the Clinical Global Impression of Change (CGIC) the clinician indicates the perceived change in patient's condition over the treatment period as compared to patient's condition prior to the start of treatment. The clinician is requested to choose one of seven categories. Scores range from very much improved to very much worse.

Time frame:
Baseline; End-of-Treatment Visit (6 weeks)
Reported as:
Count of participants · Participants
Clinical Global Impression of Change (CGIC)
ParticipantsCebranopadolMorphine Prolonged Release
Very much improved84
Much improved2026
Minimally improved109
No change75
Minimally worse36
Much worse21
Very much worse02
Missing63
Other pre-specifiedOverall Score of the Patient Assessment of Constipation Symptoms (PAC-SYM)

The PAC-SYM is a 12-item self-administered questionnaire that assesses the severity of constipation-related symptoms during past 2 weeks. Items are rated on a 5-point Likert scale, where 0 = absent, 1 = mild, 2 = moderate, 3 = severe, 4 = very severe.The PAC-SYM contains 3 subscales: stool symptoms (5 items), abdominal symptoms (4 items), rectal symptoms (3 items). If at least 6 items are assessed, the PAC-SYM overall score is calculated as the sum of the scores of all non-missing items divided by number of non-missing items. The minimum overall score is 0, the maximum overall score is 4. If more than 6 items are missing, no overall score is calculated. Changes from baseline for the overall score are presented. If the changes in the overall (or subscale) scores are positive then there is a worsening in symptoms associated with constipation.

Time frame:
Baseline; End-of-Treatment Visit (6 weeks)
Reported as:
Mean · units on a scale
Overall Score of the Patient Assessment of Constipation Symptoms (PAC-SYM)
units on a scaleCebranopadolMorphine Prolonged Release
Overall Score of the Patient Assessment of Constipation Symptoms (PAC-SYM)0.07 ± 0.5360.07 ± 0.632
Other pre-specifiedChange in Weekly Mean of the Daily Worst Pain Intensity Score From Baseline

Participants will be asked: "Please rate your pain by selecting the one number that best describes your pain at its worst during the last 24 hours." every day in the morning. They will score their pain intensity on an 11-point Numerical Rating Scale (NRS) where a score of 0 indicated "no pain" and a score of 10 indicated "pain as bad as you can imagine". The weekly mean value of the 24 h worst pain intensity will be calculated as a mean score of these daily entries of worst pain intensity for each trial week. A positive change from baseline will indicate a worsening, whilst a negative change will indicate an improvement of pain.

Time frame:
Baseline; End-of-Treatment Visit (6 weeks)
Reported as:
Mean · units on a scale
Change in Weekly Mean of the Daily Worst Pain Intensity Score From Baseline
units on a scaleCebranopadolMorphine Prolonged Release
Change in Weekly Mean of the Daily Worst Pain Intensity Score From Baseline-3.3 ± 2.68-3.3 ± 2.11
Other pre-specifiedChange From Baseline to End-of-Treatment Visit in Chronic Pain Sleep Inventory (CPSI) Scores

The CPSI measures 5 items on 100-mm visual analog scales: trouble falling asleep (CPSI1), needing sleep medication (CPSI2), awakened by pain during the night (CPSI3) and in the morning (CPSI4) \[all with anchors for 0 = never and 100 = always\], and overall quality of sleep (CPSI5) \[with anchors of 0 = very poor and 100 = excellent\]. The sleep problem index is the sum of items CPSI1, CPSI3 and CPSI4. The minimum sleep problem index is 0 mm, the maximum 300 mm, the higher the worse. For the overall quality of sleep, minimum and maximum are 0 and 100 mm, the higher the better. A decrease in the sleep problem index indicates an improvement as does an increase in the overall quality of sleep. Changes from baseline to the End-of-Treatment Visit of the Maintenance Phase (scheduled for Week 6) were calculated.

Time frame:
Baseline; End-of-Treatment Visit (6 weeks)
Reported as:
Mean · units on a scale
Change From Baseline to End-of-Treatment Visit in Chronic Pain Sleep Inventory (CPSI) Scores
units on a scaleCebranopadolMorphine Prolonged Release
Sleep Problem Index-62.7 ± 77.91-53.7 ± 77.71
Overall Quality of Sleep20.5 ± 36.118.1 ± 30.4

Adverse events

Collected over From first IMP intake up to day of last IMP in Week 6 + 3 weeks follow-up (max. 9 weeks in total). The All-Cause Mortality is reported for the Allocated Set. Serious and non-serious treatment emergent adverse events (i.e. events documented after the first dose of study medication and events which started before treatment and worsened after first dose of study medication) are reported for the Safety Set (all participants with at least one dose of study medication).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cebranopadol3/66 (4.5%)14/65 (21.5%)52/65 (80%)
Morphine Prolonged Release5/66 (7.6%)11/61 (18%)48/61 (78.7%)
Most frequent serious events
Showing 10 of 20
Most frequent serious events
EventCebranopadolMorphine Prolonged Release
Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps)5/657/61
DehydrationMetabolism and nutrition disorders1/652/61
Cardiac failureCardiac disorders0/651/61
Pulmonary embolismRespiratory, thoracic and mediastinal disorders0/651/61
AnaemiaBlood and lymphatic system disorders0/651/61
AstheniaGeneral disorders0/651/61
DiarrhoeaGastrointestinal disorders0/651/61
Small intestinal obstructionGastrointestinal disorders0/651/61
VomitingGastrointestinal disorders1/651/61
CachexiaMetabolism and nutrition disorders0/651/61
Most frequent other events
Showing 10 of 16
Most frequent other events
EventCebranopadolMorphine Prolonged Release
ConstipationGastrointestinal disorders8/6515/61
FatigueGeneral disorders7/6510/61
NauseaGastrointestinal disorders8/6510/61
Decreased appetiteMetabolism and nutrition disorders5/659/61
AstheniaGeneral disorders6/658/61
VomitingGastrointestinal disorders8/655/61
Oedema peripheralGeneral disorders7/650/61
DizzinessNervous system disorders2/656/61
Urinary tract infectionInfections and infestations2/656/61
SomnolenceNervous system disorders6/655/61

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)CebranopadolMorphine Prolonged ReleaseTotal
<=18 years000
Between 18 and 65 years363571
>=65 years292655
Age, Continuous
Age, Continuous(years)CebranopadolMorphine Prolonged ReleaseTotal
Mean63.8 ± 9.1861 ± 10.6462.4 ± 9.98
Sex: Female, Male
Sex: Female, Male(Participants)CebranopadolMorphine Prolonged ReleaseTotal
Female272249
Male383977
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)CebranopadolMorphine Prolonged ReleaseTotal
Hispanic or Latino202
Not Hispanic or Latino5860118
Unknown or Not Reported516
Race (NIH/OMB)
Race (NIH/OMB)(Participants)CebranopadolMorphine Prolonged ReleaseTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White6561126
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)CebranopadolMorphine Prolonged ReleaseTotal
Romania213
Hungary459
Spain101
Austria224
Belgium011
Denmark123
Poland161632
Slovakia131326
Bulgaria7411
Chile202
Serbia336
Germany131427
Croatia101
Prior opioid treatment
Prior opioid treatment(Participants)CebranopadolMorphine Prolonged ReleaseTotal
WHO Step II analgesic272855
WHO Step III analgesic excluding morphine222143
Morphine161228
ECOG Status
ECOG Status(Participants)CebranopadolMorphine Prolonged ReleaseTotal
Status 0171330
Status 1303060
Status 2181836
Status 3000
Status 4000
Status 5000

10 further baseline measures are reported on the registry.

09

Study locations

42 sites
  • AT004
    Vienna, 1090, Austria
  • BE005
    Brussels, 1020, Belgium
  • BE002
    Ottignies, 1340, Belgium
  • BE001
    Sint-Niklaas, 9100, Belgium
  • BG001
    Shumen, 9700, Bulgaria
  • BG008
    Sofia, 1330, Bulgaria
  • BG003
    Sofia, 1407, Bulgaria
  • BG006
    Sofia, 1756, Bulgaria
  • BG007
    Sofia, 1784, Bulgaria
  • BG004
    Varna, 9003, Bulgaria
  • BG005
    Vratsa, 3000, Bulgaria
  • CL005
    Temuco, 4810469, Chile
  • HR001
    Zagreb, 10000, Croatia
  • DK006
    Aalborg, 9000, Denmark
  • DK004
    Herlev, 2730, Denmark
  • DE008
    Böhlen, 4564, Germany
  • DE010
    München, 81377, Germany
  • HU004
    Gyula, 5700, Hungary
  • HU002
    Miskolc, 3526, Hungary
  • HU011
    Nyiregyhaza, 4400, Hungary
  • PL008
    Bydgoszcz, 85-796, Poland
  • PL012
    Będzin, 42 - 500, Poland
  • PL013
    Chorzów, 41-506, Poland
  • PL014
    Dąbrowa Górnicza, 41-300, Poland
  • PL003
    Gdansk, 80-208, Poland
  • PL010
    Gliwice, 44-100, Poland
  • PL015
    Warszawa, 01-231, Poland
  • PL002
    Wloclawek, 87-800, Poland
  • RO001
    Brasov, 500019, Romania
  • RO002
    Cluj-Napoca, 400015, Romania
  • RO009
    Constanta, 900591, Romania
  • RO011
    Craiova, 200347, Romania
  • RS001
    Belgrade, 11000, Serbia
  • RS003
    Belgrade, 11000, Serbia
  • RS002
    Sremska Kamenica, 21204, Serbia
  • RS005
    Zrenjanin, 23000, Serbia
  • SK007
    Bratislava, 81107, Slovakia
  • SK004
    Bratislava, 851 07, Slovakia
  • SK001
    Prešov, 080 01, Slovakia
  • SK005
    Pruské, 018 52, Slovakia
  • ES012
    Barcelona, 8022, Spain
  • UK004
    Leeds, LS14 6UH, United Kingdom
10

References and documents

Publications

  • Eerdekens MH, Kapanadze S, Koch ED, Kralidis G, Volkers G, Ahmedzai SH, Meissner W. Cancer-related chronic pain: Investigation of the novel analgesic drug candidate cebranopadol in a randomized, double-blind, noninferiority trial. Eur J Pain. 2019 Mar;23(3):577-588. doi: 10.1002/ejp.1331. Epub 2019 Jan 9. PubMed 30365202 ↗

Individual participant data

Plan to share: No

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2013 to primary completion in Oct 2015, 23 months.

Results were first posted in Dec 2019, 4 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 7, 2013
First posted
Oct 17, 2013
StartActual
Oct 29, 2013
Primary completionActual
Oct 16, 2015
CompletionActual
Oct 16, 2015
Results first posted
Dec 30, 2019
Last update
Jul 15, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 15, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT01964378
Lead sponsor
Tris Pharma, Inc.
Responsible party
Sponsor
First posted
Oct 17, 2013
Start date
Oct 29, 2013
Primary completion
Oct 16, 2015
Completion
Oct 16, 2015
Results posted
Dec 30, 2019
Last update
Jul 15, 2021

Study contacts

Director Clinical Trials
study director · Grünenthal GmbH

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cebranopadol

Start the discussion